Skip to main content
Erschienen in: General Thoracic and Cardiovascular Surgery 6/2017

23.02.2017 | Original Article

New PET/CT criterion for nodal staging in non-small cell lung cancer: measurement of the ratio of section area of standard uptake values ≥2.5/lymph node section area

verfasst von: Yoshitaro Saito, Kazuhiro Imai, Koichi Ishiyama, Hajime Saito, Satoru Motoyama, Yusuke Sato, Hayato Konno, Satoshi Fujishima, Manabu Hashimoto, Yoshihiro Minamiya

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of the present study was to use surgical and histological results to develop a simple noninvasive technique for improving nodal staging using preoperative PET/CT in patients with resectable non-small cell lung cancer (NSCLC).

Methods

Preoperative PET/CT findings (163 patients) and pathological diagnoses after surgical resection were evaluated. Using PET/CT images, lymph node section area (SA), the maximum standardized uptake value (SUVmax), SA of SUV ≥2.5 and ≥3.0 were drawn freehand and measured using caliper software. Receiver operating characteristic (ROC) curves were then used to analyze those data.

Results

Based on ROC analyses, the cut-off values for SA of SUV ≥2.5, SA of SUV ≥3.0, SUV ≥2.5 SA/node SA and SUV ≥3.0 SA/node SA for diagnosis of lymph node metastasis were 200 mm2, 30 mm2, 1.0 and 0.4. SUV ≥2.5 SA/node SA ≥1.0 had the highest negative predictive value, and the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of nodal staging were 61.1, 73.4, 36.7, 88.2 and 70.9%.

Conclusions

When diagnosing nodal staging based a lymph node SUV ≥2.5 SA/node SA ratio of ≥1.0, it can be an effective criterion for use to determine surgical indications.
Literatur
1.
Zurück zum Zitat Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:234S–42S.CrossRefPubMed Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:234S–42S.CrossRefPubMed
2.
Zurück zum Zitat Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol. 2008;3:84–93.CrossRefPubMed Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol. 2008;3:84–93.CrossRefPubMed
3.
Zurück zum Zitat Fukui T, Mitsudomi T. Small peripheral lung adenocarcinoma: clinicopathological features and surgical treatment. Surg Today. 2010;40:191–8.CrossRefPubMed Fukui T, Mitsudomi T. Small peripheral lung adenocarcinoma: clinicopathological features and surgical treatment. Surg Today. 2010;40:191–8.CrossRefPubMed
4.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
5.
Zurück zum Zitat Al-Shahrabani F, Vallböhmer D, Angenendt S, Knoefel WT. Surgical strategies in the therapy of non-small cell lung cancer. World J Clin Oncol. 2014;5:595–603.CrossRefPubMedPubMedCentral Al-Shahrabani F, Vallböhmer D, Angenendt S, Knoefel WT. Surgical strategies in the therapy of non-small cell lung cancer. World J Clin Oncol. 2014;5:595–603.CrossRefPubMedPubMedCentral
6.
7.
Zurück zum Zitat Imai K, Minamiya Y, Saito H, Motoyama S, Sato Y, Ito A, et al. Diagnostic imaging in the preoperative management of lung cancer. Surg Today. 2014;44:1197–206.CrossRefPubMed Imai K, Minamiya Y, Saito H, Motoyama S, Sato Y, Ito A, et al. Diagnostic imaging in the preoperative management of lung cancer. Surg Today. 2014;44:1197–206.CrossRefPubMed
8.
Zurück zum Zitat Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011–19.CrossRefPubMed Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011–19.CrossRefPubMed
9.
Zurück zum Zitat Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg. 2009;36:440–5.CrossRefPubMed Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg. 2009;36:440–5.CrossRefPubMed
10.
Zurück zum Zitat De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007;17:23–32.CrossRefPubMed De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007;17:23–32.CrossRefPubMed
11.
Zurück zum Zitat Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1145 lymph nodes. Lung Cancer. 2008;60:62–8.CrossRefPubMed Al-Sarraf N, Gately K, Lucey J, Wilson L, McGovern E, Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1145 lymph nodes. Lung Cancer. 2008;60:62–8.CrossRefPubMed
12.
Zurück zum Zitat Lv YL, Yuan DM, Wang K, Miao XH, Qian Q, Wei SZ, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol. 2011;6:1350–8.CrossRefPubMed Lv YL, Yuan DM, Wang K, Miao XH, Qian Q, Wei SZ, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol. 2011;6:1350–8.CrossRefPubMed
13.
Zurück zum Zitat Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology. 2008;246:772–82.CrossRefPubMed Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology. 2008;246:772–82.CrossRefPubMed
14.
Zurück zum Zitat Weng E, Tran L, Rege S, Safa A, Sadeghi A, Juillard G, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol. 2000;23:47–52.CrossRefPubMed Weng E, Tran L, Rege S, Safa A, Sadeghi A, Juillard G, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol. 2000;23:47–52.CrossRefPubMed
15.
Zurück zum Zitat Changlai SP, Tsai SC, Chou MC, Ho YJ, Kao CH. Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep. 2001;8:337–9.PubMed Changlai SP, Tsai SC, Chou MC, Ho YJ, Kao CH. Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep. 2001;8:337–9.PubMed
16.
Zurück zum Zitat Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40:271–4.CrossRefPubMed Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40:271–4.CrossRefPubMed
17.
Zurück zum Zitat Jones DR, Stiles BM, Denlinger CE, Antippa P, Daniel TM. Pulmonary segmentectomy: results and complications. Ann Thorac Surg. 2003;76:343–9.CrossRefPubMed Jones DR, Stiles BM, Denlinger CE, Antippa P, Daniel TM. Pulmonary segmentectomy: results and complications. Ann Thorac Surg. 2003;76:343–9.CrossRefPubMed
18.
Zurück zum Zitat Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132:769–75.CrossRefPubMed Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg. 2006;132:769–75.CrossRefPubMed
19.
Zurück zum Zitat Schuchert MJ, Pettiford BL, Keeley S, D’Amato TA, Kilic A, Close J, et al. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:926–33.CrossRefPubMed Schuchert MJ, Pettiford BL, Keeley S, D’Amato TA, Kilic A, Close J, et al. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:926–33.CrossRefPubMed
20.
Zurück zum Zitat Kudo S, Imai K, Ishiyama K, Hashimoto M, Saito H, Motoyama S, et al. New CT criteria for nodal staging in non-small cell lung cancer. Clin Imaging. 2014;38:448–53.CrossRefPubMed Kudo S, Imai K, Ishiyama K, Hashimoto M, Saito H, Motoyama S, et al. New CT criteria for nodal staging in non-small cell lung cancer. Clin Imaging. 2014;38:448–53.CrossRefPubMed
21.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind Ch (eds). TNM classification of malignant tumours, 7th Edition. New York: Wiley-Blackwell, 2009. Sobin LH, Gospodarowicz MK, Wittekind Ch (eds). TNM classification of malignant tumours, 7th Edition. New York: Wiley-Blackwell, 2009.
22.
Zurück zum Zitat Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;35:179–87.CrossRefPubMed Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;35:179–87.CrossRefPubMed
23.
Zurück zum Zitat Moloney F, Ryan D, McCarthy L, McCarthy J, Burke L, Henry MT, et al. Increasing the accuracy of18F-FDG PET/CT interpretation of “mildly positive” mediastinal nodes in the staging of non-small cell lung cancer. Eur J Radiol. 2014;83:843–7.CrossRefPubMed Moloney F, Ryan D, McCarthy L, McCarthy J, Burke L, Henry MT, et al. Increasing the accuracy of18F-FDG PET/CT interpretation of “mildly positive” mediastinal nodes in the staging of non-small cell lung cancer. Eur J Radiol. 2014;83:843–7.CrossRefPubMed
24.
Zurück zum Zitat Hanley JA, McNeil BJ. A method of comparing the area under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–43.CrossRefPubMed Hanley JA, McNeil BJ. A method of comparing the area under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–43.CrossRefPubMed
25.
Zurück zum Zitat Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (1 cm), intermediate (1 to 3 cm), and large (3 cm) lymph node lesions. Chest. 2000;117:773–8.CrossRefPubMed Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (1 cm), intermediate (1 to 3 cm), and large (3 cm) lymph node lesions. Chest. 2000;117:773–8.CrossRefPubMed
26.
Zurück zum Zitat Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18 F-FDG. J Nucl Med. 2003;44:1426–31.PubMed Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18 F-FDG. J Nucl Med. 2003;44:1426–31.PubMed
27.
Zurück zum Zitat Cobben DC, Elsinga PH, Hoekstra HJ, Suurmeijer AJ, Vaalburg W, Maas B, et al. Is 18 F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med. 2004;45:1677–82.PubMed Cobben DC, Elsinga PH, Hoekstra HJ, Suurmeijer AJ, Vaalburg W, Maas B, et al. Is 18 F-3′-fluoro-3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med. 2004;45:1677–82.PubMed
28.
Zurück zum Zitat Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwil C, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging. 2005;32:525–33.CrossRefPubMed Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwil C, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging. 2005;32:525–33.CrossRefPubMed
29.
Zurück zum Zitat Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, et al. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008;35:236–45.CrossRefPubMed Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, et al. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008;35:236–45.CrossRefPubMed
30.
Zurück zum Zitat Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA. Evaluation of thoracic tumor with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393–401.CrossRefPubMed Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA. Evaluation of thoracic tumor with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393–401.CrossRefPubMed
31.
Zurück zum Zitat Minamimoto R, Toyohara J, Ito H, Seike A, Miyata Y, Morooka M, et al. A pilot study of 4′-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer. EJNMMI Res. 2014;4:10.CrossRefPubMedPubMedCentral Minamimoto R, Toyohara J, Ito H, Seike A, Miyata Y, Morooka M, et al. A pilot study of 4′-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer. EJNMMI Res. 2014;4:10.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Toyohara J, Sakata M, Oda K, Ishii K, Ishiwata K. Longitudinal observation of [11C] 4DST uptake in turpentine-induced inflammatory tissue. Nucl Med Biol. 2013;40:240–4.CrossRefPubMed Toyohara J, Sakata M, Oda K, Ishii K, Ishiwata K. Longitudinal observation of [11C] 4DST uptake in turpentine-induced inflammatory tissue. Nucl Med Biol. 2013;40:240–4.CrossRefPubMed
33.
Zurück zum Zitat Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002;38:261–6.CrossRefPubMed Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002;38:261–6.CrossRefPubMed
34.
Zurück zum Zitat Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131:255–60.CrossRefPubMed Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131:255–60.CrossRefPubMed
35.
Zurück zum Zitat Booth K, Hanna GG, McGonigle N, McManus KG, McGuigan J, O’Sullivan J, et al. The mediastinal staging accuracy of 18F-Fluorodeoxyglycose positron emission tomography/computed tomography in non-small cell lung cancer with variable time intervals to surgery. Ulster Med J. 2013;82:75–81.PubMedPubMedCentral Booth K, Hanna GG, McGonigle N, McManus KG, McGuigan J, O’Sullivan J, et al. The mediastinal staging accuracy of 18F-Fluorodeoxyglycose positron emission tomography/computed tomography in non-small cell lung cancer with variable time intervals to surgery. Ulster Med J. 2013;82:75–81.PubMedPubMedCentral
36.
Zurück zum Zitat Kim DH, Song BI, Hong CM, Jeong SY, Lee SW, Lee J, et al. Metabolic parameters using 18F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2051–7.CrossRefPubMed Kim DH, Song BI, Hong CM, Jeong SY, Lee SW, Lee J, et al. Metabolic parameters using 18F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2051–7.CrossRefPubMed
37.
Zurück zum Zitat Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–61.CrossRefPubMed Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–61.CrossRefPubMed
38.
Zurück zum Zitat van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. The Lancet. 2002;359:1388–93.CrossRef van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. The Lancet. 2002;359:1388–93.CrossRef
Metadaten
Titel
New PET/CT criterion for nodal staging in non-small cell lung cancer: measurement of the ratio of section area of standard uptake values ≥2.5/lymph node section area
verfasst von
Yoshitaro Saito
Kazuhiro Imai
Koichi Ishiyama
Hajime Saito
Satoru Motoyama
Yusuke Sato
Hayato Konno
Satoshi Fujishima
Manabu Hashimoto
Yoshihiro Minamiya
Publikationsdatum
23.02.2017
Verlag
Springer Japan
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 6/2017
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-017-0756-2

Weitere Artikel der Ausgabe 6/2017

General Thoracic and Cardiovascular Surgery 6/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.